New pill CTX001 aims to fix iron issues – first human tests begin
NCT ID NCT07577817
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called CTX001 in 72 healthy adults. The goal is to check for side effects and see how the drug affects iron levels in the blood, with or without iron supplements and food. It is a first step toward possibly treating anemia and iron deficiencies in people with chronic kidney disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CTX001 (tablet)
- What this could lead to
- If successful, this could point toward a new treatment for iron-related problems in conditions like anemia and chronic kidney disease.
- What could go wrong
- This is a very early Phase 1 trial in only 72 healthy people, so it may not work or be safe in patients. Side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nucleus Network
RECRUITINGMelbourne, Victoria, 3004, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can less be more? testing transfusion limits in ECMO
- Aging kidneys under the microscope: could a simple test predict failure?
- A simple blood test trend may flag ICU patients at risk
- Could your gut bacteria hold the key to protecting your kidneys?
- Food as medicine: could cooking classes slow kidney disease?
- Rethinking anemia: does blood hemoglobin tell the whole story?